OpZira, Inc., a forward-thinking ophthalmic medical device company, has secured $1.1 million in funding from investors. This capital infusion marks a significant step for the company, which is built on a legacy of research excellence and dedicated to delivering innovative technologies designed to enhance the detection and monitoring of ocular disease.
The company's portfolio includes two primary offerings. The AdaptDx Pro® is a wearable dark adaptometer that leverages AI to ensure a consistent patient experience. This device is crucial for identifying impaired dark adaptation speed, often one of the first functional signs of retinal disease, and is currently available in the U.S. OpZira also offers the EVERGE™ Vision Testing System, a robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. Its VEP component is available in the U.S. and select international markets, while ERG is available outside of the U.S.
This recent funding round underscores investor confidence in OpZira's technology and its potential impact on ophthalmic diagnostics. The company plans to strategically deploy the $1.1 million to accelerate its growth initiatives, further develop its existing technology portfolio, and expand its market reach. This investment is expected to support ongoing research and development efforts aimed at enhancing its diagnostic capabilities.
The successful close of this funding round positions OpZira to continue its mission of advancing ophthalmic care. By strengthening its operational capacity and expanding its commercial footprint, OpZira aims to bring its innovative diagnostic solutions to more patients and clinicians globally, ultimately improving early detection and management of ocular conditions.
